Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2017 / Articles / Sep / Serialization Blind Spots
Manufacture Standards & Regulation Technology and Equipment Business Practice Packaging Trends & Forecasts Business & Trends Facilities & Equipment Technology & Manufacturing Packaging

Serialization Blind Spots

With all the complications of serialization, it’s easy to overlook a few key areas.

By Pavel Lotkov 09/20/2017 1 min read

Share

Serialization used to be a very technical, internal problem, mainly focused on packaging lines. Over time, the focus shifted to managing the impact on business operations in warehousing and distribution, with increasing oversight by quality and compliance organizations. While some companies are still focused on getting their packaging lines serialized, others are now dealing with the external dimension of serialization – facing government reporting and data sharing challenges. This is especially true for large global companies with very diverse business operations and a complex supply chain. Though today’s challenge may still seem packaging line-focused, tomorrow’s challenge will be based on data management and the ability to derive business intelligence from billions or even trillions of data points.

Data One aspect of serialization that some companies overlook is the fact that it’s a complex data management problem (or opportunity) that impacts multiple departments within their organization. Serialization needs to be handled as a corporate-level program, led by a program manager and a team of experts who are able to analyze the impacts, as well as identify and communicate the long-term vision and opportunities. Points of failure A lot of companies will also soon face issues with operational sustainability. As more and more products are serialized and the number of the externally facing transactions increases, the number of failures to be dealt with will increase as well. Companies that focused on a “happy path” scenario and did not invest sufficient time in failure management will find themselves out of capacity, and having to deal with the mounting weight of failed transactions that need to be investigated and corrected. It is important to carefully consider all possible failure points inside and outside the walls of the company, and then ensure that the business processes, as well as technical solutions, are capable of supporting the rectification process in an efficient way.

Business process There is a lot of focus on packaging and specific technology, while problems could often be downstream from packaging and related to a business process failure or lack of business process altogether. It is important to initially consider the impact on operations across the wide spectrum of affected departments, and then design the new business processes while taking into account the possible technical challenges. When this is done and agreed upon by stakeholders, it is crucial to communicate with the affected areas within the company so they are prepared to absorb the new process and technology. Counterfeiting This isn’t really an oversight, but I think it’s worth mentioning that serialization will not completely stop counterfeiting, but it will certainly make the legitimate supply chain more secure, at least for some time. Counterfeiting is a very profitable business and criminals will continue looking for ways around it. As for those online pharmacies that pretend to be legal but instead are illicit drug outlets, they will continue to sell fake drugs to unsuspecting consumers. The fight against counterfeit medicine needs to include continual consumer education and roll-out of technology that will allow consumers to verify drug authenticity themselves. If implemented right, serialization will allow companies to put mechanisms in place to prevent product diversion and parallel importation, improve supply chain visibility, provide direct links to the patient, and offer vast amount of business intelligence data. Serialization certainly remains relevant today and will continue to be relevant for many years to come. Companies that understand this and plan for it by investing in the right technology will see that future – while others may cease to exist.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Pavel Lotkov

Pavel Lotkov is the Product Director at Adents.

More Articles by Pavel Lotkov

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Regulators Target Ebola
Standards & Regulation
Regulators Target Ebola

December 1, 2014

0 min read

Will FDA fast review and voucher incentives make a difference?

Safety First - Sizing Up Biologics Side Effects
Standards & Regulation Biosimilars
Safety First - Sizing Up Biologics Side Effects

December 2, 2014

0 min read

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.

United Science Stands
Small Molecules Standards & Regulation
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.